Develops dietary supplements that increase NAD+ levels for healthy aging.
Jun 2026Revenue $129M/yrExpenses $118M/yr
Reached break-even Sep 2024
Figures by year
When did Niagen Bioscience become profitable?
Its revenue passed its expenses in Sep 2024. In the 12 months to Jun 2026, revenue was $129M and expenses $118M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $129M | $113M | $16.3M |
| Dec 2024 | $99.6M | $91.9M | $7.73M |
| Dec 2023 | $83.6M | $89.2M | −$5.60M |
| Dec 2022 | $72.0M | $90.7M | −$18.6M |
| Dec 2021 | $67.4M | $94.5M | −$27.1M |
| Dec 2020 | $59.3M | $79.1M | −$19.9M |
| Dec 2019 | $46.3M | $77.6M | −$31.3M |
| Dec 2018 | $31.6M | $64.7M | −$33.2M |
| Dec 2017 | $21.2M | $37.6M | −$16.4M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.